Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Neurokinin receptor
    (6)
  • Others
    (2)
TargetMol | Tags By ResearchField
  • Nervous System
    (5)
  • Endocrine system
    (2)
  • Cancer
    (1)
Filter
Search Result
Results for "

rat nk1 receptor

" in TargetMol Product Catalog.
  • Inhibitors & Agonists
    8
    TargetMol | All_Pathways
  • Peptide Products
    4
    TargetMol | Peptide_Products
  • Vofopitant
    GR 205171
    T13329168266-90-8In house
    Vofopitant (GR 205171) is a potent NK1 receptor antagonist with anxiolytic and antiemetic activity for the study of post-traumatic stress disorder (PTSD).
    • $100
    In Stock
    Size
    QTY
  • Vofopitant dihydrochloride
    Vofopitant 2HCl, GR 205171A
    T13329L168266-51-1In house
    Vofopitant dihydrochloride (GR 205171A) is an orally available, selective tachykinin NK1 receptor antagonist that inhibits [3H]SP binding to NK1 with pKi values of 9.5 and 10.6, respectively. It is a potential compound for the treatment of pathological vomiting.
    • $100
    In Stock
    Size
    QTY
  • GR-203040 HCl
    GR-203040 hydrochloride, GR-203040, GR203040, GR 203040
    T24102168398-02-5
    GR203040 inhibits cyclophosphamide-induced damage in the rat and ferret bladder. GR-203040 is a selective NK1 receptor antagonist.
    • $2,520
    35 days
    Size
    QTY
  • Nolpitantium Free Base
    T70456155418-05-6
    Nolpitantium Free Base is a highly selective nonpeptide antagonist of neurokinin-1 (NK1) receptor. Nolpitantium potently, selectively and competitively inhibited substance P binding to NK1 receptors from various animal species, including humans. In vitro, it was a potent antagonist in functional assays for NK1 receptors such as [Sar9, Met(O2)11]substance P-induced endothelium-dependent relaxation of rabbit pulmonary artery and contraction of guinea-pig ileum. Up to 1 mkM, Nolpitantium had no effect in bioassays for NK2 and NK3 receptors. The antagonism exerted by Nolpitantium toward NK1 receptors was apparently non-competitive, with pD2' values between 9.65 and 10.16 in the different assays. Nolpitantium also blocked in vitro [Sar9, Met(O2)11]substance P-induced release of acetylcholine from rat striatum. In vivo, Nolpitantium exerted highly potent antagonism toward [Sar9, Met(O2)11]substance P-induced hypotension in dogs, bronchoconstriction in guinea-pig) and plasma extrava......
    • $3,020
    10-14 weeks
    Size
    QTY
  • GR 64349 TFA
    T75881
    GR 64349 is a potent and highly selective NK2 receptor peptide antagonist with an EC50 of 3.7 nM in rat colon, exhibiting over 1000-fold selectivity against NK1 receptors and over 300-fold selectivity against NK3 receptors, ensuring targeted action [1] [2].
    • Inquiry Price
    Inquiry
    Size
    QTY
  • [Sar9,Met(O2)11]-Substance P TFA(110880-55-2,free)
    [Sar9,Met(O2)11]-Substance P TFA
    TP1369
    [Sar9,Met(O2)11]-Substance P TFA is a selective tachykinin NK1 receptor agonist.[Sar9,Met(O2)11]-Substance P and septide (10-100 pmol per rat, i.c.v.) are equipotent in increasing mean arterial blood pressure (MAP) and heart rate (HR), yet they have dissi
    • $76
    Inquiry
    Size
    QTY
  • [Sar9,Met(O2)11]-Substance P acetate
    [Sar9,Met(O2)11]-Substance P acetate(110880-55-2 free base)
    TP1369L
    [Sar9,Met(O2)11]-Substance P acetate is a tachykinin NK1 receptor selective agonist. [Sar9,Met(O2)11]-Substance P acetate is a selective tachykinin NK1 receptor agonist.[Sar9,Met(O2)11]-Substance P acetate and septide (10-100 pmol per rat, i.c.v.) are equipotent in increasing mean arterial blood pressure (MAP) and heart rate (HR), yet they have dissimilar time-course. Both agonists increase dose-dependently face washing and sniffing while [Sar9,Met(O2)11]-Substance P acetate is the sole to produce grooming.
    • $55
    In Stock
    Size
    QTY
  • GR 64349
    TP2023137593-52-3
    Potent and selective tachykinin NK2 receptor agonist (EC50 = 3.7 nM in rat colon). Displays > 1000- and > 300-fold selectivity over NK1 and NK3 receptors respectively. Active in vivo.
    • $1,750
    35 days
    Size
    QTY